Charlie's Holdings Q1 Revenue +204% to $4.8M; Net Loss $(1.05)M
Charlie's Holdings, Inc. reported a significant increase in product revenue for Q1 2026, reaching $4.804 million, a 204% rise from the prior year. The company also reduced its net loss from continuing operations to $1.050 million, down from $1.269 million in Q1 2025. Despite ongoing regulatory challenges, including Marketing Denial Orders from the FDA for certain products, the company improved its working capital to $4.843 million and fully satisfied two related-party notes payable, while extending the maturity of a $2.0 million secured related-party note.
Key Highlights
- Product revenue for Q1 2026 increased 204% to $4.804 million.
- Net loss from continuing operations improved to $(1.050) million in Q1 2026.
- Working capital increased to $4.843 million as of March 31, 2026.
- Net cash used in operating activities was $(1.105) million for Q1 2026.
- Two related-party notes payable, totaling $238K, were fully satisfied.
- A $2.0 million secured related-party note's maturity was extended to June 1, 2027.
- Received FDA Marketing Denial Order on April 1, 2026, for certain 2020 PMTAs.
- Fifth Circuit granted a stay on December 24, 2025, for MDOs on synthetic nicotine products.
Price Impact
More from CHUC
Charlie's Holdings Names Henry Sicignano III CEO; Ryan Stump Transitions
Charlie's Holdings Stockholders Approve Reverse Split, Equity Plan Increase
Charlie's Holdings Sells 6.35M Shares for $1.27M in Private Placement